Moderna Is Up Over 600% This Year. Here's What Jim Cramer Learned in His Exclusive
3 Articles
3 Articles
Is Moderna's Cancer Vaccine a Game Changer for the Stock?
Key PointsIntismeran and Keytruda have demonstrated in clinical trials that they can drastically improve outcomes for melanoma patients.The combined treatment has reduced the risk of death and melanoma spreading or returning.The vaccine isn't approved yet, however, and there will be challenges with producing it at a significant scale.10 stocks we like better than Moderna › The market has been wildly excited about Moderna (NASDAQ:MRNA) this year,…
Moderna Is Up Over 600% This Year. Here's What Jim Cramer Learned in His Exclusive
One melanoma headline turned a $63 stock into a market darling, and Moderna's CEO just told Jim Cramer when patients could get the shot. Does the price already bake in the cancer breakthrough, or is the next catalyst still ahead?
Moderna Is Up Over 600% This Year. Here’s What Jim Cramer Learned in His Exclusive
The post Moderna Is Up Over 600% This Year. Here’s What Jim Cramer Learned in His Exclusive appeared first on 24/7 Wall St.. Moderna (NASDAQ:MRNA) shares have gained 638% in 2026. The past week showed how quickly a move like that can give ground: the stock dropped 14.33%. Jim Cramer interviewed…
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium






